Observational studyIn vivo (Athens, Greece)
Serum Zinc Levels and Skin-related Adverse Events During Systemic Therapy for Renal Cell Carcinoma.
Observational study in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis study aimed to evaluate the association between serum zinc levels and skin-related adverse events in patients with advanced or metastatic renal cell carcinoma receiving systemic drug therapy. PATIENTS AND
methodsThis retrospective observational study included 25 patients with unresectable or metastatic renal cell carcinoma (RCC) who initiated systemic therapy between September 2018 and September 2023. Serum zinc levels were measured at multiple time points during treatment, and skin-related adverse events were graded according to CTCAE version 5.0.
resultsThe median age was 73 years, and 76% of patients were male. Skin-related adverse events occurred in 12 patients (48%), with grade 3 or higher events in four patients (16%). A progressive decline in zinc levels was observed in 15 patients (60%) during treatment. Among seven patients with zinc levels measured at the time of adverse event occurrence, six (85.7%) exhibited decreased zinc levels compared to baseline.
conclusionThis study provides preliminary evidence of an association between zinc depletion and skin-related adverse events in patients with renal cell carcinoma receiving systemic therapy. Zinc monitoring may represent an underutilized strategy for optimizing patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.